Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial - Wikidata - awgldk - TriplyDB

Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial

Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial

http://www.wikidata.org/entity/Q34694778

about

Use of Direct Oral Anticoagulants in Patients With Atrial Fibrillation and Valvular Heart Lesions Direct oral anticoagulant use in nonvalvular atrial fibrillation with valvular heart disease: a systematic review Stroke Prevention in Atrial Fibrillation and Valvular Heart Disease.Non-Vitamin K Oral Anticoagulants for Stroke Prevention in Special Populations with Atrial Fibrillation.Anticoagulation in Atrial Fibrillation - Current Concepts Native valve disease in patients with non-valvular atrial fibrillation on warfarin or rivaroxaban Resolution of massive left atrial appendage thrombi with rivaroxaban before balloon mitral commissurotomy in severe mitral stenosis: A case report and literature review.Risk factors associated with bleeding after multi antithrombotic therapy during implantation of cardiac implantable electronic devices.Impact of valvular heart disease on oral anticoagulant therapy in non-valvular atrial fibrillation: results from the RAMSES study.Evolving cardiovascular uses of direct-acting oral anticoagulants: a paradigm shift on the horizon?2017 consensus of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation.ANMCO Position Paper: direct oral anticoagulants for stroke prevention in atrial fibrillation: clinical scenarios and future perspectives.Effects of Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: A Systematic Review and Meta-Analysis.Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 1.Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: Executive summary.Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Clinical Practice.New frontiers in anticoagulation: non vitamin-K oral anticoagulants in stroke prevention.Safety and Feasibility of Treatment with Rivaroxaban for Non-Canonical Indications: A Case Series Analysis.Stroke prevention strategies in patients with atrial fibrillation and heart valve abnormalities: perceptions of 'valvular' atrial fibrillation: results of the European Heart Rhythm Association Survey.The year in cardiology 2015: valvular heart disease.Apixaban-Induced Resolution of A Massive Left Atrial and Appendage Thrombosis in a Very Elderly Patient.Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and valvular heart disease: systematic review and meta-analysis.Dilemmas in the use of new oral anticoagulants.2017 Focused Update for Management of Patients With Valvular Heart Disease: Summary of New Recommendations.Prevalence, Characteristics, and Outcomes of Valvular Heart Disease in Patients With Atrial Fibrillation: Insights From the ORBIT-AF (Outcomes Registry for Better Informed Treatment for Atrial Fibrillation).2017 ESC/EACTS Guidelines for the management of valvular heart disease.Arrhythmias: drugs and devices.Safety and Efficacy of Novel Oral Anticoagulants Versus Warfarin in Medicare Beneficiaries With Atrial Fibrillation and Valvular Heart Disease.Direct Oral Anticoagulants in Dental Patients Including the Frail Elderly Population.Oral anticoagulant use for stroke prevention in atrial fibrillation patients with difficult scenarios

P2860

Q26764853-B3EC036E-A80C-4AD5-B432-59BAE6B075C7 Q28071807-F6E8C414-43DF-48D6-AC0F-AA6D6F5C3E06 Q30389813-E26E3DE2-531D-471E-84DF-44B488AD05B0 Q33844478-F0E34CB2-25DD-4A4F-A9CF-2E69F0BB9296 Q36458853-76EFC2D5-4B74-4ACE-8801-B35984C7C810 Q37085638-E3F487DE-3D29-4BF5-9A34-FB0E02C06F12 Q37606144-22DAEE18-FC5B-4BA9-BB75-C8A6FFA03DD8 Q37677988-91818465-8A72-4AC1-A0E4-6FA49CE9FF08 Q38384634-BC12B536-0764-4526-A6D3-F9596540EC5A Q38635568-8F575F20-0DDD-4743-9D51-A886386A224B Q38647787-06E47CD7-A4B9-433E-9439-1056F018802D Q38650658-88A770DB-86E3-48D1-8EEF-7292872380EF Q38673244-0A968B46-9343-42F4-BE98-F86E107FB2E0 Q38723866-1D2B1FC9-DC62-4A53-81F8-B7116861499B Q38860492-E44939C6-30F8-4A33-8EC1-8051B6376E39 Q38953655-0158475D-EE3E-4FFA-899A-875371370CF5 Q39027027-4474EE64-B371-4433-AEFA-7BE58BD96469 Q39612619-122374D3-ED07-467C-AE11-81AA221961F2 Q40461490-873175D1-A1DD-4240-B158-B2B617B2F09A Q40847130-2BB8135C-EF6A-414A-A1AD-CB7CD61E8B7F Q47245138-609850F4-4935-45BF-89CA-6D8F80C97311 Q47918560-7F53A4C9-BBFF-400F-88D9-DC2F4DD7AA56 Q48350779-45D2ADB4-18BA-46AD-AF40-31A955352538 Q49516122-C11DE113-77EC-4D8D-B75B-4360EEFFFA3F Q49607144-A73B1226-E090-4322-BE13-CFEF48299199 Q50196541-08053316-F89B-47D9-ACD2-6FBA13A6E39D Q51838722-E6191B57-0DE1-4CE9-AA08-7D867EBE6786 Q52603887-A861C44D-654C-463D-BE04-4CB54F385764 Q55050376-5CC3FB0C-644A-47CC-A4BC-AB248505A868 Q58781692-24C71B55-B02F-42A0-96CF-E72570DD3A30

P2860

Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial

http://www.wikidata.org/entity/Q34694778

description

2014 nî lūn-bûn

@nan

2014 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Clinical characteristics and o ...... ipating in the ROCKET AF trial

@ast

Clinical characteristics and o ...... ipating in the ROCKET AF trial

@en

Clinical characteristics and o ...... ipating in the ROCKET AF trial

@nl

type

label

Clinical characteristics and o ...... ipating in the ROCKET AF trial

@ast

Clinical characteristics and o ...... ipating in the ROCKET AF trial

@en

Clinical characteristics and o ...... ipating in the ROCKET AF trial

@nl

prefLabel

Clinical characteristics and o ...... ipating in the ROCKET AF trial

@ast

Clinical characteristics and o ...... ipating in the ROCKET AF trial

@en

Clinical characteristics and o ...... ipating in the ROCKET AF trial

@nl

P1433

Q34694778-44B76BEC-C66F-4072-A0A4-46F455209CE4

P1476

Q34694778-67C1130F-A59A-41D7-BFBA-2F5A37508259

P2093

Q34694778-0B0DDDFF-62D6-4216-999A-A86CD2DAF8B4

Q34694778-2E3991F0-171F-4B5C-9578-25A8F9BD11A3

Q34694778-4144A54F-5707-4D6B-87F5-56A393A4BCFC

Q34694778-73E52D11-2CEB-46D1-8E68-E92FD528916C

Q34694778-745565A6-64C9-4AD6-90B0-CCA92B341D0B

Q34694778-816FAF64-9ED4-4AFB-8C2B-74DAD3FA5F14

Q34694778-84A8F829-EB7E-46B2-8BD4-00B6F62AF88B

Q34694778-92144865-C3B7-4481-84B9-5A73BDE8FD69

Q34694778-95C4A163-7C14-4ACE-BF5F-0BDA800D3E09

Q34694778-E5FD977F-CD31-4B0F-BD91-DAAE27C3A55F

P2860

Q34694778-0067C43B-2CD4-4E06-98FE-25A372B0023C

Q34694778-0078A71D-C187-4CB9-B823-1235026A19C6

Q34694778-1335488B-DB53-4762-89F6-2A5E8732BE68

Q34694778-1D794CD5-1B92-4135-8DA4-41CFEF7E3F8B

Q34694778-270D269B-E810-4679-8301-0B3ADF51E50F

Q34694778-33B9A781-B15F-46F3-AF78-83B679E600EA

Q34694778-3963C1E7-FCF0-4E30-848F-35EA8C165A35

Q34694778-45271256-B116-4DF7-9ECE-32A5C7AF87DD

Q34694778-49E36CBF-9103-4721-989B-CE16B53B0511

Q34694778-5B179E33-CC69-48C8-9736-AE2CCF74200A

P304

Q34694778-968C4D5F-25F7-432A-9107-ED900F2D0D38

P31

Q34694778-3D3B5AFA-E765-44EA-A1FE-D1C3ACD29D5C

P356

Q34694778-62235F1A-C17B-4103-AFD0-07BD1A2F73C2

P433

Q34694778-EF63DAB1-B444-4C9A-AED2-39613A4EC300

P478

Q34694778-79D2E75D-8EF8-465C-9DF9-4BD080FAF7F7

P50

Q34694778-056E3738-D314-4D43-9822-F25F7E805D4D

Q34694778-12BD4CB6-4D2C-46BA-9501-59879AEC46A0

Q34694778-89A0DF19-6D0E-4F0D-A245-6B7F030FF567

Q34694778-8DD62D00-5DCC-4294-8B2D-AE6F65E44DE9

Q34694778-B523EE2B-A2FD-421A-A0C9-67574A216629

Q34694778-F898B71E-06CF-4FA8-9114-CEFE1D783834

Q34694778-FD9D2BF6-7044-481A-9788-5A4CDA18A3D1

P577

Q34694778-67E07BE8-5FF9-4DB7-B2A3-D63345333A3F

P5875

Q34694778-28B32EF1-4D87-48F0-83B9-19745FCA63CA

P698

Q34694778-DA2C010F-7BBA-4B5A-B2A8-C9D0C7122720

P921

Q34694778-68E50A82-B868-4E37-9AAA-2ECB7F811A72

Q34694778-6DA510FB-7C46-467B-A4FA-C7AFF78D7200

Q34694778-78AAF8CE-7CBF-42D6-8767-A2B22F210FD3

P932

Q34694778-B93FD0A0-56B9-47A5-885E-4DD24CCBC1D8

P356

P1433

European Heart Journal

P1476

Clinical characteristics and o ...... ipating in the ROCKET AF trial

@en

P2093

Anne S Hellkamp

http://www.w3.org/2001/XMLSchema#string

Christopher C Nessel

http://www.w3.org/2001/XMLSchema#string

Daniel E Singer

http://www.w3.org/2001/XMLSchema#string

Helmut Baumgartner

http://www.w3.org/2001/XMLSchema#string

Keith A A Fox

http://www.w3.org/2001/XMLSchema#string

Manesh R Patel

http://www.w3.org/2001/XMLSchema#string

ROCKET AF Steering Committee & Investigators

http://www.w3.org/2001/XMLSchema#string

Richard C Becker

http://www.w3.org/2001/XMLSchema#string

Scott D Berkowitz

http://www.w3.org/2001/XMLSchema#string

Susanna R Stevens

http://www.w3.org/2001/XMLSchema#string

P2860

Rationale and design of ACTIVE: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events

Dabigatran versus warfarin in patients with atrial fibrillation

2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society

2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation

Apixaban versus warfarin in patients with atrial fibrillation

Edoxaban versus warfarin in patients with atrial fibrillation

Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidelines on atrial fibrillation: primary results of the PREvention oF thromboemolic events--European Registry in Atrial Fibrillation (PREFER in AF)

A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey.

Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly

P304

3377-3385

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/EURHEARTJ/EHU305

http://www.w3.org/2001/XMLSchema#string

P433

47

http://www.w3.org/2001/XMLSchema#string

P478

35

http://www.w3.org/2001/XMLSchema#string

P50

Graeme J. Hankey

Jonathan L. Halperin

Kenneth W Mahaffey

Günter Breithardt

Jonathan P Piccini

Yuliya Lokhnygina

P577

2014-08-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

264985567

http://www.w3.org/2001/XMLSchema#string

P698

25148838

http://www.w3.org/2001/XMLSchema#string

P921

atrial fibrillation

P932

4265383

http://www.w3.org/2001/XMLSchema#string